Logo

Cellular Genomics in Initial Close of $22.3M Series C Financing

Jan 21, 2004

NEW YORK, Jan. 21 (GenomeWeb News) - Branford, Conn.-based Cellular Genomics today announced the initial closing on a $22.3 million Series C round of venture-capital financing.

 

Lilly BioVentures, and has been joined by new investors Coastview Capital and Emerging Technology Partners, as well as existing investors including Connecticut Innovations, Flagship Ventures, MPM Capital, and Vector Fund Management, the company said.

 

The company said it will use the funds to push its drug-discovery programs in cancer, angiogenesis, and autoimmune/inflammatory diseases into clinical development and to achieve key clinical milestones.

 

Cellular Genomics is developing a chemical genetics platform (Analog Sensitive Kinase Allele, or ASKA, technology) to discover and develop kinase and other signal transduction inhibitors for multiple clinical indications.

Breaking News
The Scan

Billions for Antivirals

The US is putting $3.2 billion toward a program to develop antivirals to treat COVID-19 in its early stages, the Wall Street Journal reports.

NFT of the Web

Tim Berners-Lee, who developed the World Wide Web, is auctioning its original source code as a non-fungible token, Reuters reports.

23andMe on the Nasdaq

23andMe's shares rose more than 20 percent following its merger with a special purpose acquisition company, as GenomeWeb has reported.

Science Papers Present GWAS of Brain Structure, System for Controlled Gene Transfer

In Science this week: genome-wide association study ties variants to white matter stricture in the brain, and more.